evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,320 questions · 4,561 findings · 388 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,138 · 25%GRADE not reported 886 · 19.4%Very low 1,014 · 22.2%Low 849 · 18.6%Moderate 543 · 11.9%High 131 · 2.9%

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo mouthwash

Change in haemoglobin level from baseline · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…

The review found no eligible studies for this question.

1 finding from 1 review

Late treatment (one-phase) with removable functional appliance vs no treatment

Incidence of incisal trauma · Adolescents (age 12 to 16 years) receiving orthodontic treatment to correct prominent upper front teeth (Class II malocclusion)

The review found no eligible studies for this question.

1 finding from 1 review

Removable functional appliance vs Fixed functional appliance

Final overjet · Adolescents (age 12 to 16 years) receiving orthodontic treatment to correct prominent upper front teeth (Class II malocclusion)

Removable functional appliance may leads to higher final overjet compared with fixed functional appliance (low certainty).

1 finding from 1 review

Midazolam (any mode of delivery) vs Different dosage of the same sedative

Behaviour · Children and adolescents (0 to 16 years) needing dental treatment
1 finding from 1 review
  • Sedation of children undergoing dental treatment 2018 · Cochrane All outcomes
    Any behavioural score - Midazolam (any mode of delivery): 394 (10 studies); VERY LOW. Insufficient evidence to determine whether any specific dose of intranasal midazolam is effective; weak evidence oral midazolam…
    10 studies · 394 participants
    Very low

Ty21a vaccine (three doses) vs control

Cases of typhoid fever, Year 1 · adults and children aged 5 years of age and older

Ty21a vaccine (three doses) probably leads to lower cases of typhoid fever, Year 1 compared with control (moderate certainty).

2 findings from 1 review

Vi‐rEPA vaccine (2 doses) vs control

Incidence of typhoid fever – year 1 · adults and children of 2 years of age and older

Vi‐rEPA vaccine (2 doses) probably leads to lower incidence of typhoid fever – year 1 compared with control (moderate certainty).

1 finding from 1 review

Vi‐rEPA vaccine (2 doses) vs control

Incidence of typhoid fever – year 2 · adults and children of 2 years of age and older

Vi‐rEPA vaccine (2 doses) probably leads to lower incidence of typhoid fever – year 2 compared with control (moderate certainty).

1 finding from 1 review

Vi‐rEPA vaccine (2 doses) vs control

Fever · adults and children of 2 years of age and older

Vi‐rEPA vaccine (2 doses) probably leads to higher fever after Vi‐rEPA (dose1) compared with control (moderate certainty).

1 finding from 1 review

Vi‐rEPA vaccine (2 doses) vs control

Fever after Vi‐rEPA (dose2) · adults and children of 2 years of age and older

Vi‐rEPA vaccine (2 doses) probably leads to higher fever after Vi‐rEPA (dose2) compared with control (moderate certainty).

1 finding from 1 review

Vi‐rEPA vaccine (2 doses) vs control

Erythema · adults and children of 2 years of age and older

Vi‐rEPA vaccine (2 doses) showed no clear difference in erythema after Vi‐rEPA (dose 2) compared with control (low certainty).

1 finding from 1 review

Vi‐rEPA vaccine (2 doses) vs control

Swelling at injection site after Vi‐rEPA (dose 2) · adults and children of 2 years of age and older

Vi‐rEPA vaccine (2 doses) probably leads to higher swelling at injection site after Vi‐rEPA (dose 2) compared with control (moderate certainty).

1 finding from 1 review